Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 3:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 617 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: blood transfusion Clear all
Completed Not applicable Interventional Results available

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
Drug · Behavioral · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?

NCT02918851
View directory record Official record
Conditions
Healthy
Interventions
Transfusion of 7-day stored red blood cells, Transfusion of 28-day stored red blood cells, Transfusion of 42-day stored red blood cells
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 12, 2026, 3:06 PM EDT
Withdrawn Early Phase 1 Interventional

Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation

NCT04383756
View directory record Official record
Conditions
Transfusion Related Complication, Liver Transplant
Interventions
Donor Blood, Banked Blood
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Red Cell Storage Duration Study

NCT00991341
View directory record Official record
Conditions
Cardiac Surgery, Erythrocyte Transfusion
Interventions
Red blood cell units stored <= 10 days, Red blood cell units stored >= 21 days
Biological
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
1,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
33
States / cities
Gainesville, Florida • Atlanta, Georgia • Fort Wayne, Indiana + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion Pilot

NCT01167582
View directory record Official record
Conditions
Myocardial Infarction, Unstable Angina, Coronary Artery Disease
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 12, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Transfusion of Biotin-Labeled Red Blood Cells

NCT03364686
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Biotin-Labeled Red Blood Cells
Biological
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 12, 2026, 3:06 PM EDT
Terminated Phase 1Phase 2 Interventional

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

NCT03933813
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions
Iron Sucrose
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants

NCT01523769
View directory record Official record
Conditions
Prematurity
Interventions
Umbilical Cord Milking
Procedure
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing, Implementing and Evaluating Effective Community-facility Interactions to Improve Blood Availability and Transfusion in Three Distinct County Settings in Kenya

NCT06142825
View directory record Official record
Conditions
Blood Transfusion
Interventions
Community-Facility Transfusion Committee (CFTC)
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

NCT00153985
View directory record Official record
Conditions
Hemoglobinopathies, Sickle Cell Disease, Thalassemia
Interventions
Busulfex, Fludarabine, Alemtuzumab, Stem Cell Transfusion
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

NCT00656448
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Procrit
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 12, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

NCT03381833
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
LJPC-401
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
14 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 12, 2026, 3:06 PM EDT
Active, not recruiting Not applicable Interventional

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

NCT05405426
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Interventions
Red blood cell transfusion
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 12, 2026, 3:06 PM EDT
Recruiting Phase 1 Interventional

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

NCT03591302
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total Lymphoid irradiation
Biological · Radiation
Lead sponsor
Stephan Busque
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis

NCT01137656
View directory record Official record
Conditions
Healthy
Interventions
Acetylcholine and Blood
Drug
Lead sponsor
Mark Gladwin
Other
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty

NCT01370460
View directory record Official record
Conditions
Acute Blood Loss Anemia, Osteoarthritis, Knee
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 12, 2026, 3:06 PM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Not applicable Interventional Results available

Red Cell Storage Duration and Outcomes in Cardiac Surgery

NCT00458783
View directory record Official record
Conditions
Blood Transfusion, Cardiac Surgery
Interventions
Prolonged RBC storage, Short RBC storage
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

NCT02269280
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 12, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional Results available

Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

NCT01204788
View directory record Official record
Conditions
Leukemia
Interventions
Prophylactic White Cell Transfusion, Therapeutic White Cell Transfusion
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 12, 2026, 3:06 PM EDT
Completed Not applicable Interventional

Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery

NCT00320619
View directory record Official record
Conditions
Scoliosis, Kyphosis, Lordosis, Spondylitis, Spinal Stenosis
Interventions
Epsilon-Aminocaproic Acid (EACA), Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 12, 2026, 3:06 PM EDT
Terminated Early Phase 1 Interventional

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

NCT05841706
View directory record Official record
Conditions
Resectable Pancreatic Carcinoma
Interventions
Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL), Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL), Computed Tomography, X-Ray Imaging, Biospecimen Collection, Survey Administration, Pancreatectomy
Biological · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 12, 2026, 3:06 PM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 12, 2026, 3:06 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Luspatercept + Darbepoetin in MDS

NCT07096297
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
Luspatercept, Darbeopoetin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 12, 2026, 3:06 PM EDT